Targovax ASA News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.06.20	Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses (PR Newswire)
04.06.20	Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses (PR Newswire)
14.05.20	Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO (PR Newswire)
14.05.20	Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO (PR Newswire)
06.05.20	Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO (PR Newswire)
06.05.20	Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO (PR Newswire)
04.05.20	Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy (PR Newswire)
04.05.20	Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy (PR Newswire)
30.04.20	Targovax ASA Appoints Dr Victor Levitsky as Chief Scientific Officer (PR Newswire)
30.04.20	Targovax ASA Appoints Dr Victor Levitsky as Chief Scientific Officer (PR Newswire)
22.04.20	Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology (PR Newswire)
22.04.20	Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology (PR Newswire)
03.04.20	Targovax ASA Announces Proposed New Chairman of the Board (PR Newswire)
03.04.20	Targovax ASA Announces Proposed New Chairman of the Board (PR Newswire)
11.03.20	Targovax ASA: Fourth Quarter 2019 Results (PR Newswire)
11.03.20	Targovax ASA: Fourth Quarter 2019 Results (PR Newswire)
10.03.20	Ausblick: Targovax ASA legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
03.03.20	Targovax Announces Completed Enrollment in the ONCOS-102 Trial in Anti-PD1 Refractory Melanoma (PR Newswire)
03.03.20	Targovax Announces Completed Enrollment in the ONCOS-102 Trial in Anti-PD1 Refractory Melanoma (PR Newswire)
21.01.20	Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy (PR Newswire)
21.01.20	Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy (PR Newswire)
08.01.20	Updated Press Release: Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China (PR Newswire)
08.01.20	Updated Press Release: Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China (PR Newswire)
11.11.19	Presentation of ONCOS-102 Melanoma Data at SITC Annual Meeting (PR Newswire)
11.11.19	Presentation of ONCOS-102 Melanoma Data at SITC Annual Meeting (PR Newswire)
07.11.19	Targovax ASA: Third Quarter 2019 Results (PR Newswire)
07.11.19	Targovax ASA: Third Quarter 2019 Results (PR Newswire)
09.10.19	Targovax Selected for Oral Presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting (PR Newswire)
09.10.19	Targovax Selected for Oral Presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting (PR Newswire)
08.07.19	Targovax Announces Encouraging Results From Part 1 of the ONCOS-102 and Keytruda Combination Trial in Anti-PD1 Refractory Melanoma (PR Newswire)
08.07.19	Targovax Announces Encouraging Results From Part 1 of the ONCOS-102 and Keytruda Combination Trial in Anti-PD1 Refractory Melanoma (PR Newswire)
03.06.19	Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination (PR Newswire)
03.06.19	Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination (PR Newswire)
23.05.19	Targovax to Fully Focus on ONCOS Oncolytic Virus Program (PR Newswire)
23.05.19	Targovax to Fully Focus on ONCOS Oncolytic Virus Program (PR Newswire)
09.05.19	Targovax ASA: First Quarter 2019 Results (PR Newswire)
09.05.19	Targovax ASA: First Quarter 2019 Results (PR Newswire)
08.05.19	Targovax Announces Completed Enrollment of ONCOS-102 Trial in Mesothelioma (PR Newswire)
08.05.19	Targovax Announces Completed Enrollment of ONCOS-102 Trial in Mesothelioma (PR Newswire)
14.03.19	Targovax Grants Zelluna Immunotherapy an FTO License to Intellectual Property Relating to Mutant Ras T Cell Receptor Technology (PR Newswire)
14.03.19	Targovax Grants Zelluna Immunotherapy an FTO License to Intellectual Property Relating to Mutant Ras T Cell Receptor Technology (PR Newswire)
14.02.19	Targovax ASA: Fourth Quarter and Full Year 2018 Results (PR Newswire)
14.02.19	Targovax ASA: Fourth Quarter and Full Year 2018 Results (PR Newswire)
13.02.19	Ausblick: Targovax ASA öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
21.01.19	Targovax is Invited to Present at Upcoming Investor Conferences (PR Newswire)
21.01.19	Targovax is Invited to Present at Upcoming Investor Conferences (PR Newswire)
17.01.19	Targovax Granted European Patent for Mutant-RAS Neoantigen Platform Lead Products (PR Newswire)
17.01.19	Targovax Granted European Patent for Mutant-RAS Neoantigen Platform Lead Products (PR Newswire)
12.12.18	Targovax Presents at DNB 9th Annual Nordic Healthcare Conference (PR Newswire)
12.12.18	Targovax Presents at DNB 9th Annual Nordic Healthcare Conference (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Targovax ASA

Aktien Top/Flop

Meistgelesene Nachrichten